RE:AstraZeneca's ADC disappoints - on severe adverse eventsJanuary 17, 2024 - U.S. PTO invalidates Seagen ADC patent and rule in foavor of Daiichi Sankyo..
In its final decision, the U.S. PTO invalidated all of the claims in Seagen’s patent 10,808,039, which covers the use of auristatin peptides connected to antibody-drug conjugates (ADCs) via a specific linker technology.
The patent dispute between Daiichi Sankyo and Seagen goes back to 2008, when the two companies entered into an exclusive worldwide agreement to leverage the latter’s ADC platform to target solid tumors.
https://www.biospace.com/article/uspto-rules-against-seagen-in-adc-patent-battle-with-daiichi-sankyo-/